Viatris Inc
NASDAQ:VTRS
Operating Margin
Viatris Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Viatris Inc
NASDAQ:VTRS
|
10.5B USD |
11%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
185.9B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.3B USD |
27%
|
Viatris Inc
Glance View
In the bustling realm of pharmaceutical giants, Viatris Inc. has carved out a distinctive path since its inception in November 2020, born from the merger of Mylan N.V. and Pfizer’s Upjohn division. This union forged a new entity poised to leverage a vast portfolio of iconic brands and generic drugs. At its core, Viatris operates on a diversified business model, producing and distributing therapeutic solutions that range from well-known branded medications to complex generics and over-the-counter (OTC) products. With operations spanning across the globe, the company ensures the delivery of critical healthcare solutions to millions, focusing on accessibility and affordability. This global approach not only enhances its revenue streams but also strengthens its market resilience against regional disruptions. Strategically, Viatris has placed a hefty emphasis on integrating and optimizing supply chains, thereby maximizing operational efficiencies and profit margins. By successfully blending the robust generic drug capabilities of Mylan with the established brand strength of Pfizer’s Upjohn, Viatris is well-positioned to capture and sustain market share across diverse therapeutic categories. Additionally, Viatris invests heavily in research and development to expand its pipeline of complex generics and biosimilars, potentially paving the way for future growth and innovation. This strategic alignment allows the company to cater to a broad spectrum of patient needs and healthcare systems worldwide, making it a formidable player in the pharmaceutical industry.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Viatris Inc's most recent financial statements, the company has Operating Margin of 10.6%.
You don't have any saved screeners yet